Research news

Peptides, longevity and geroscience research watch.

General educational updates on emerging research. This page is designed to inform, not recommend treatment.

Educational research updates only — not medical advice.

This research library is provided for general educational and informational purposes only. It does not recommend, prescribe, endorse, advertise or supply any peptide, drug, supplement, compounded product or longevity intervention. Articles may discuss investigational, preclinical, off-label or emerging research that has not been proven safe or effective for individual patients and may not be approved by Australian regulators or other health authorities for the uses discussed. Patients must not start, stop or change any treatment based on this page. Personal medical decisions require an individual consultation with an appropriately qualified clinician who can review history, medications, risks, pathology and current evidence.

Peptides · Pinned

MOTS-c: mitochondrial-derived peptide research in metabolism, stress and ageing

PubMed-linked review watch

MOTS-c remains an active research topic because mitochondrial-derived peptides may connect metabolic stress, exercise biology and ageing pathways. Current patient-facing framing should stay cautious: interesting biology, not a clinical recommendation.

Evidence: Review. Published/updated: 2025-01-01.

Clinician note: Discuss only as emerging mitochondrial peptide science. Do not imply availability, suitability or clinical benefit.

Read source

GLP-1 · Pinned

GLP-1 medicines and longevity claims: promising mechanisms, but microdosing claims remain unproven

PubMed clinical literature watch

GLP-1 receptor agonists are being discussed in longevity circles because of weight, metabolic and inflammatory mechanisms. The library should clearly separate approved medical uses from unproven longevity or microdosing claims.

Evidence: Human data. Published/updated: 2025-01-01.

Clinician note: State that any GLP-1 use is a medical decision requiring proper indication, monitoring and risk review.

Read source

Peptides

Peptide drug-development tools: predicting peptide lipophilicity and delivery barriers

Open scientific preprint / peptide development methods

New computational approaches are being developed to predict peptide properties such as lipophilicity, which matters because many peptides face stability and delivery barriers. This helps explain why promising peptide biology often does not immediately become safe clinical care.

Evidence: Computational. Published/updated: 2025-05-22.

Clinician note: Useful as a safety/context article: promising peptide claims need pharmacology, dosing and clinical validation.

Read source

Senescence

FOXO4-DRI and senescent-cell targeting: preclinical senolytic peptide research

PubMed senescence research watch

FOXO4-DRI is a synthetic peptide studied as a senescence-targeting strategy in preclinical ageing models. This belongs in the research-news category, not treatment guidance, because translation to patient care remains unresolved.

Evidence: Preclinical. Published/updated: 2025-01-01.

Clinician note: Use strong investigational language. Avoid patient-use or sourcing discussion.

Read source

Peptides

Apelin peptide signalling and muscle ageing

PubMed muscle ageing research watch

Apelin biology is being investigated in relation to muscle ageing, exercise response, mitochondrial function and inflammation. This is useful for patient education about mechanisms, not peptide treatment advice.

Evidence: Preclinical. Published/updated: 2025-01-01.

Clinician note: Keep the patient takeaway focused on exercise, muscle preservation and research literacy.

Read source